A

Patient Specific Panels (fingerprint size)

	Clinical Benefit											No Clinical Benefit				
	306 (57)	**314** (45)	**332** (6)	**358** (50)	**361** (63)	**369** (39)	**378** (76)	**434** (120)	**452** (52)	**518** (51)	**520** (32)	**315** (76)	**357** (36)	**376** (75)	**389** (90)	**393** (37)
T1	30	1	0	9	53	31	64	7	0	35	8	26	24	27	71	21
T2	7	0	NA	8	7	5	10	NA	0	NA	NA	24	24	26	65	22
T3	3	NA	NA	NA	24	3	NA	NA	NA	NA	NA	24	26	16	NA	NA
T4	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	23	NA	NA	NA
HD	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1

(Time Points shown along rows T1–T4, HD)

MRD+   # MRD-   NA Sample Unavailable

SNVs Detected

B

C

D

Supplementary Figure 11: **MRD testing in newly diagnosed, metastatic BC patients.** (A) Number of mutations detected for each patient's sample. Each patient's panel was additionally applied to healthy donors as a specificity check. (B) Tumor fraction estimates for each patient's sample over course of treatment, stratified by clinical benefit. (C) Tumor fraction fold change between first two timepoints, stratified by clinical benefit. Confidence intervals were re-calculated using the Delta Method. (D) Tumor fractions for MRD+ samples split by the minimum fingerprint size required to still detect MRD.